2. Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

3. ARIC PCSK9 Loss-of-Function Mutations, LDL-C, and CHD Risk

7. PCSK9-Directed Therapies in Development

8. Effects of Evolocumab (AMG-145) on LDL-C Levels Phase 1b Study Design

9. Evolocumab -- Phase 1b Change in LDL-C at 2- and 4-Week Dosing Intervals on Statin Therapy

10. PCSK9 Inhibitors Phase 2

11. MENDEL Evolocumab Phase 2 Monotherapy in Patients With Hypercholesterolemia

12. MENDEL Study Design

13. MENDEL Evolocumab Monotherapy for Hypercholesterolemia

14. PCSK9 Inhibitors Phase 2

15. Alirocumab (SAR236553) Add-on to Atorvastatin

16. Alirocumab Change in LDL-C at 2- and 4-Week Dosing Intervals on Atorvastatin

17. Alirocumab on Top of Atorvastatin in Primary Hypercholesterolemia

18. LAPLACE-TIMI 57 Evolocumab in Combination With Statin in Patients With Hypercholesterolemia

19. LAPLACE-TIMI 57 Study Design

20. LAPLACE-TIMI 57 Effect of Evolocumab on Percentage Change in LDL-C From Baseline

21. Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Phase 2 Studies

22. Intravenous RN316 in Hypercholesterolemic Patients on High- or Maximum-Dose Statin Therapy Doses Studied

23. Intravenous RN316 in Hypercholesterolemic Patients on High or Maximum-Dose Statin Therapy Pooled Results

24. PCSK9 Inhibitors Phase 2

25. GAUSS Phase 2 Evolocumab in Statin-Intolerant Patients

26. GAUSS Evolocumab in Statin Intolerance

27. PCSK9 Inhibitors Phase 2

28. Effect of Alirocumab on LDL-C in Heterozygous FH

29. RUTHERFORD Phase 2 Evolocumab in Patients With Heterozygous FH

30. RUTHERFORD Effect of Evolocumab on LDL-C in Heterozygous FH

31. Phase 3 Trials

32. OSLER Phase 3 Extension Study

33. OSLER Effect of Evolocumab on LDL-C after 52 Weeks

34. ODYSSEY Outcomes Phase 3 Post-ACS With Alirocumab

38. References

39. References (cont)

40. References (cont)